588.34
-8.51(-1.43%)
Currency In USD
| Previous Close | 596.85 |
| Open | 586.85 |
| Day High | 591.64 |
| Day Low | 582.37 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 520.5 |
| Volume | 653,859 |
| Average Volume | 1.15M |
| Market Cap | 62.45B |
| PE | 14.96 |
| EPS | 39.33 |
| Moving Average 50 Days | 600.5 |
| Moving Average 200 Days | 804.9 |
| Change | -8.51 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,161.28 as of May 24, 2025 at a share price of $588.34. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,079.11 as of May 24, 2025 at a share price of $588.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
GlobeNewswire Inc.
May 19, 2025 11:07 AM GMT
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned pur
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
GlobeNewswire Inc.
May 15, 2025 6:02 PM GMT
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damage
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire Inc.
Apr 28, 2025 11:01 AM GMT
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARR